An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

India introduces Qartemi a groundbreaking CAR-T cell therapy to fight advanced blood cancers like B-cell Non-Hodgkin Lymphoma ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy ... Aggressive B-Cell Lymphoma June 19, 2024 ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

Moreover, advancements in immunotherapy, particularly targeting ... dogs diagnosed with this aggressive cancer. Diffuse Large B-Cell Lymphoma (DLBCL): A type of cancer that originates in B-cells ...

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, ...